Sword Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital physical therapy platform. $4B valuation. $240M ARR, cash-flow positive. 2,500+ employers. Founded 2015, Porto/NYC. Raised $340M+. Private.
About
Sword Health is a digital musculoskeletal care company founded in 2015 and headquartered in New York City with engineering roots in Porto, Portugal. The company was founded by physical therapist and engineer Virgílio Bento with the mission of freeing two billion people from pain using AI-powered physical therapy that matches or exceeds the clinical outcomes of in-person care. Sword pioneered the use of sensor-equipped motion trackers combined with AI therapy guidance delivered through a tablet interface.\n\nSword's platform pairs each member with a licensed physical therapist who designs and supervises a personalized program, while an AI engine called Phoenix handles real-time biomechanical coaching during sessions, monitors adherence, and flags clinical concerns for human review. Programs cover the full MSK spectrum — back, neck, shoulder, hip, knee, and post-surgical rehabilitation — as well as pelvic health through its Bloom product. Sword sells to self-insured employers and health plans; it has contracted with more than 2,500 enterprise customers including major Fortune 500 companies.\n\nSword reached $240 million in annualized recurring revenue and achieved cash-flow positivity, a rare milestone among digital health companies at its stage. The company has raised more than $340 million in total funding, reaching a $4 billion valuation. Its clinical evidence base — spanning dozens of peer-reviewed studies demonstrating meaningful pain reduction and return-to-work rates — differentiates Sword in a crowded MSK market and supports its position as the leading AI-native physical therapy platform.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.